AVA 202
Alternative Names: Angiogenic Exosome - Avalon GloboCare/Weill Cornell Medicine; AVA-202Latest Information Update: 28 Aug 2023
At a glance
- Originator Avalon GloboCare; Weill Cornell Medicine
- Class Anti-ischaemics; Exosome therapies; Vascular disorder therapies
- Mechanism of Action Angiogenesis inducing agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic foot ulcer; Vascular disorders
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in USA
- 28 Aug 2023 No recent reports of development identified for preclinical development in Vascular-disorders in USA
- 24 Jul 2019 Avalon GloboCare plans IND enabling studies in vascular disorder in Q2 2019 (Avalon GloboCare pipeline, July 2019)